Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Seattle, Washington 98108


The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.


Inclusion Criteria: - give voluntary signed informed consent - have histologically documented prostate cancer - have been on ADT treatment for 6 months prior to randomization or intermittent LHRHa for preceeding 12 months - expected to continue LHRHa therapy uninterrupted for the next 12 months - have total testosterone levels less than 50 ng/dL - Have BMD of lumbar spine or femoral neck at or below the BMD thresholds - have a Zubrod performance status <or equal to 1 - subject weight <300 lbs(<136 kg) - agree to complete a daily diary of medication intake - agree not to take excluded medications throughout the trial - agree to use an effective method of contraception - have adequate bone marrow, liver and renal functions Exclusion Criteria: - Currently or previously exposed - within the past 5 years to intravenous bisphosphonates, strontium ranelate or Denosumab - for more than 3 years to oral bisphosphonates - within the last 45 days to PTH or PTH derivative, anabolic steroids or testosterone, SERMs, calcitonin, calcitriol or oral gluccorticoids - have any disease or condition that would preclude an accurate evaluation of radiographs of the thoracic or lumbar spine - have <8 evaluable vertebrae - have a BMD T score <-4 at the lumbar spine or total hip or femoral neck - have any history of other carcinomas within the last 5 years - Serum PSA > 5ng/mL at baseline under ADT - have Paget's disease, Cushing's disease, chronic hepatitis or cirrhosis or rheumatoid arthritis - have active uncontrolled systemic viral, bacterial or fungal infections - have a clinically significant concurrent illness or psychological, familial, sociological, geograhical or other condition that would not permit adequate follow-up and compliance - received treatment with other investigational agents within 30 days - taking finasteride, dutasteride, danazol or testosterone like substances - taking herbal medicines or dietary supplements - have a history of thromboembolic disease including DVT or pulmonary embolus - have a QTcF of > or equal to 450 msec or congenital or acquired QTc prolongation - have HIV - calcicum urolithiasis prohibiting the use of vitamin D

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:


Brief Title:

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

Official Title:

Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy

Overall Status:


Study Phase:

Phase 3



Minimum Age:

50 Years

Maximum Age:

80 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

cost of conducting the study and increased

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification: S

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Mitchell Steiner, MD
Study Director

Study Dates

Start Date:March 2011
Completion Date:September 2011
Completion Type:Actual
Primary Completion Date:September 2011
Primary Completion Type:Actual
Verification Date:November 2013
Last Changed Date:November 13, 2013
First Received Date:October 1, 2010

Study Outcomes

Outcome Type:Primary Outcome
Measure:To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures
Time Frame:36 months
Safety Issues:False

Study Interventions

Intervention Type:Drug
Description:Toremifene 80mg daily

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:GTx
Agency Class:Industry
Agency Type:Collaborator
Agency Name:Ipsen

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.